Roles of UBE2C in breast cancer and its clinical significance

Abstract

Qin Tao, Li Man.. Roles of UBE2C in breast cancer and its clinical significance[J]. Journal of International Oncology, 2015, 42(10): 766-768.

［1］ Zhou MJ, Chen FZ, Chen HC. Ubiquitination involved enzymes and cancer［J］. Med Oncol, 2014, 31(8): 93. ［2］ Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitoticspecific ubiquitinconjugating enzyme UbcH10［J］. J Biol Chem, 2002, 277(24): 21913-21921. ［3］ Nath S, Banerjee T, Sen D, et al. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10［J］. J Biol Chem, 2011, 286(18): 15666-15677. ［4］ Meyer HJ, Rape M. Processive ubiquitin chain formation by the anaphasepromoting complex［J］. Semin Cell Dev Biol, 2011, 22(6): 544-550. ［5］ Rape M, Reddy SK, Kirschner MW. The processivity of multiubiquitination by the APC determines the order of substrate degradation［J］. Cell, 2006, 124(1): 89-103. ［6］ Hao Z, Zhang H, Cowell J. Ubiquitinconjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker［J］. Tumour Biol, 2012, 33(3): 723-730. ［7］ Berlingieri MT, Pallante P, Sboner A, et al. UbcH10 is overexpressed in malignant breast carcinomas［J］. Eur J Cancer, 2007, 43(18): 2729-2735. ［8］ Rawat A, Gopal G, Selvaluxmy G, et al. Inhibition of ubiquitin conjugating enzyme UBE2C reducesproliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole［J］. Cell Oncol, 2013, 36(6): 459-467. ［9］ Endesfelder D, Burrell R, Kanu N, et al. Chromosomal instability selects gene copy number variants encoding core regulators of proliferation in ER+ breast cancer［J］. Cancer Res, 2014, 74(17): 4853-4863. ［10］ Fujita T, Ikeda H, Kawasaki K, et al. Clinicopathological relevance of UbcH10 in breast cancer［J］. Cancer Sci, 2009, 100(2): 238-248. ［11］ Lu J, Wen M, Huang Y, et al. C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes［J］. Epigenetics, 2013, 8(6): 571-583. ［12］ Wang S, Rijk JC, Pen MJ, et al. A lowdensity DNA microchip for the detection of (anti)estrogenic compounds and their relative potencies［J］. Analytical Biochemistry, 2013, 435(1): 83-92. ［13］ Lai HW, Chien SY, Kuo SJ, et al. The potential utility of curcumin in the treatment of HER2overexpressed breast cancer: an in vitro and in vivo comparison study with herceptin［J］. Evid Based Complement Alternat Med, 2012, 2012: 486568. ［14］王银平, 殷志强, 陈雪华. UbcH10在乳腺癌中的表达及意义［J］. 外科理论与实践, 2008, 13(2): 149-152. ［15］ Jancík S, Drábek J, Radzioch D, et al. Clinical relevance of KRAS in human cancers［J］. J Biomed Biotechnol, 2010, 2010: 150960. ［16］ Chou CP, Huang NC, Jhuang SJ, et al. Ubiquitinconjugating enzyme UBE2C is highly expressed in breast microcalcification lesions［J］. PLoS One, 2014, 9(4): e93934. ［17］ Loussouarn D, Campion L, Leclair F, et al. Validation of UBE2C protein as a prognostic marker in nodepositive breastcancer［J］. Br J Cancer, 2009, 101(1): 166-173. ［18］ Taylor KJ, Sims AH, Liang L, et al. Dynamic changes in gene expression in vivo predict prognosis of tamoxifentreated patients with breast cancer［J］. Breast Cancer Res, 2010, 12(3): R39.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin.Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer[J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei.Clinical application of PARP inhibitors in breast cancer[J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654.

Roles of UBE2C in breast cancer and its clinical significance

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments